PACTR201412000959159已完成未知
Randomized, single blind, cross-over study to evaluate the palatability of new orally disintegrating tablets of PZQ and L-PZQ versus current PZQ tablets in African children age 6-11 years
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Merck KGaA
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 Year(s) 至 11 Year(s)(—)
- 性别
- All
入选标准
- •1.Children male or female aged 6-11 years (inclusive)
- •2.Parents or guardians gave written informed consent prior to any trial related procedure and child gave assent
- •3.Able to communicate well with the Investigator, understanding the protocol requirements and restrictions, and willing to comply with the requirements of the entire trial
- •4.Subjects should be able to hold 2 milliliter (mL) of any appropriate juice in their mouth for 10 seconds without swallowing it and to keep a candy in the mouth for 20 seconds without swallowing it
- •5.Children who are able to properly assess and differentiate flavours of different soft drinks
- •6.Children who are able to use a hedonic scale (children will be trained before the study)
排除标准
- •1.Unlikely to comply with the protocol requirements, instructions and trial-related restrictions, example: uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial
- •2.Children with any condition or dietary habit known to interfere with the sense of smell and taste, ingestion of any medication (except paracetamol)
- •3.Children with significant illness in the previous 2 weeks
- •4.Any surgical or medical condition, or any significant disease that in the opinion of the investigator, constitutes a risk or a contraindication for the participation of the subject in the study that could interfere with the study objectives, conduct or evaluation
- •5.Children who have participated in any clinical investigation within the previous 4 weeks
研究者
相似试验
撤回
1 期
A trial to evaluate the effect of Flex-Aid beverage on frequency of nocturnal foot and/or leg cramps and its safety and tolerabilityACTRN12615001245583Flex Pharma, Inc.80
进行中(未招募)
1 期
Study of the effect and safety of a new immunoglobulin preparation (HyQvia) for subcutaneous usage in patients with Multifocal Motor NeuropathyMultifocal Motor Neuropathy (MMN)MedDRA version: 18.1Level: PTClassification code 10064135Term: Polyneuropathy chronicSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-003453-18-DKRigshospitalet20
进行中(未招募)
不适用
Patient preferences for Eucreas® versus Victoza® in Type 2 Diabetes mellitus patientstype 2 diabetes mellitusMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-003818-16-DEovartis Pharma GmbH
已完成
2 期
A study on the efficacy of icatibant for sweating-induced dermal paiJPRN-jRCTs061210021Takahagi Shunsuke10
进行中(未招募)
1 期
A research study to compare two treatments for treating a respiratory disease known as asthma-COPD overlap syndrome (ACOS).EUCTR2015-002046-31-HUMundipharma Research Limited130
